ARK Genomic Revolution ETF vs Zillow Group Inc Class A — how do they compare? ARK Genomic Revolution ETF trades at $44.61, while Zillow Group Inc Class A trades at $34.4 (market cap $7.68B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| ARKG | ZG | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $44.55 | $86.76 |
52-Week Low | $24.02 | $29.14 |
Market Cap | — | $7.68B |
Enterprise Value | — | $7.56B |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $44.69 with a 0.86% daily gain, showing bullish momentum with strong moving average signals but overbought oscillators. The ETF focuses on genomic revolution companies with 59% concentration in top 10 holdings and long-term EPS growth of 10.7%. Recent news highlights biotech sector strength and ARKG's recovery from July correction.
Outlook remains positive given biotech sector tailwinds including FDA friendliness and AI-driven drug discovery, though high RSI readings suggest near-term caution. Key risks include sector volatility and concentrated portfolio exposure.
Zillow Group (ZG) trades at $33.46, down 1.81% with a bearish technical signal. The company shows improving fundamentals with Q2 2026 earnings beats and 18% revenue growth, though net margins remain thin at 1.96%. Recent news highlights strong performance in the preferred agent model but is overshadowed by multiple securities class action lawsuits with August 2026 deadlines. Valuation metrics appear elevated with a P/E of 149, while analyst consensus targets $47.56 with mixed ratings.
The outlook is cautiously optimistic given ZG's business model transition and revenue growth, but significant legal overhangs and high valuation create near-term risks. Long-term potential exists if monetization improvements continue, though investors should weigh legal uncertainties against fundamental progress.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →